Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Multiple MyelomaMyeloma MultipleKahler DiseaseMyeloma, Plasma CellMyeloma-MultipleMyelomatosisPlasma Cell Myeloma
Interventions
DRUG

Selinexor

oral drug that comes in 20 mg tablets

DRUG

Dexamethasone Oral

Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.

DRUG

Daratumumab

"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."

DRUG

Lenalidomide

Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle

Trial Locations (10)

12206

New York Oncology Hematology, P.C., Albany

20155

Virginia Cancer Specialists, PC, Gainesville

21044

Maryland Oncology Hematology, P.A., Columbia

75702

Texas Oncology, P.A., Tyler

76104

Texas Oncology, P.A., Fort Worth

78240

Texas Oncology, P.A., San Antonio

78705

Texas Oncology, P.A., Austin

80218

Rocky Mountain Cancer Centers, Denver

85711

Arizona Oncology Associates, PC - HOPE, Tucson

97401

Willamette Valley Cancer Institute and Research Center, Eugene

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

US Oncology Research

INDUSTRY

NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter